41425411000001101: Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd) (product)

• SNOMED CT Concept\Pharmaceutical / biologic product\...
• \UK product\Actual medicinal product\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \UK product\Virtual medicinal product\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \UK product\Virtual therapeutic moiety\Erlotinib\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \UK product\Virtual therapeutic moiety\Erlotinib\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing erlotinib\Erlotinib\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing erlotinib\Erlotinib\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing erlotinib\Product containing erlotinib in oral dose form (medicinal product form)\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Product containing protein-tyrosine kinase inhibitor\Product containing erlotinib\Erlotinib\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Product containing protein-tyrosine kinase inhibitor\Product containing erlotinib\Erlotinib\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by disposition\Product containing enzyme inhibitor\Product containing transferase inhibitor\Product containing phosphotransferase inhibitor\Product containing protein kinase inhibitor\Product containing protein-tyrosine kinase inhibitor\Product containing erlotinib\Product containing erlotinib in oral dose form (medicinal product form)\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by structure\Product containing substance with ether structure (product)\Product containing erlotinib\Erlotinib\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by structure\Product containing substance with ether structure (product)\Product containing erlotinib\Erlotinib\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by structure\Product containing substance with ether structure (product)\Product containing erlotinib\Product containing erlotinib in oral dose form (medicinal product form)\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by structure\Product containing quinazoline\Product containing erlotinib\Erlotinib\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by structure\Product containing quinazoline\Product containing erlotinib\Erlotinib\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by structure\Product containing quinazoline\Product containing erlotinib\Product containing erlotinib in oral dose form (medicinal product form)\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing erlotinib\Erlotinib\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing erlotinib\Erlotinib\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Medicinal product categorized by therapeutic role\Medicinal product acting as antineoplastic agent (product)\Medicinal product containing epidermal growth factor receptor antagonist and acting as antineoplastic agent (product)\Product containing erlotinib\Product containing erlotinib in oral dose form (medicinal product form)\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)
• \Medicinal product\Product manufactured as oral dose form\Product containing erlotinib in oral dose form (medicinal product form)\Product containing only erlotinib in oral dose form (medicinal product form)\Product containing precisely erlotinib (as erlotinib hydrochloride) 25 milligram/1 each conventional release oral tablet\Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 15-Feb 2023. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id	Description	Lang	Type	Status	Case?	Module
2608081000001116	Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd)	en	Synonym	Active	Entire term case sensitive	SNOMED CT United Kingdom drug extension module
2608091000001119	Erlotinib 25mg tablets (Glenmark Pharmaceuticals Europe Ltd) (product)	en	Fully specified name	Active	Entire term case sensitive	SNOMED CT United Kingdom drug extension module

Expanded Value Set

This concept is not in any reference sets

Back to Start